N-linked protein glycosylation
Log in to starNucleotides, heme, and glycosylation
Last updated Nov 4, 2026
Log in to add personal notes on this page.
Many proteins need sugar chains (glycans) attached to work. In N-linked glycosylation, a glycan is assembled on a lipid carrier in the endoplasmic reticulum, transferred onto asparagine residues of newly made proteins, and then completed. The pathway depends on a steady supply of activated mannose. Because so many proteins carry these glycans, a defect anywhere gives a multisystem disorder with prominent neurologic disease, and one blood glycoprotein, transferrin, shows the defect.
- glucose → fructose-6-phosphate ⇄ mannose-6-phosphate: mannose phosphate isomerase (MPI) links glycolysis to mannose; dietary mannose also enters as mannose-6-phosphate. Inhibited by fructose-1-phosphate in hereditary fructose intolerance, a secondary defect.
- mannose-6-phosphate → mannose-1-phosphate: phosphomannomutase 2 (PMM2). Blocked in PMM2-CDG.
- mannose-1-phosphate → GDP-mannose: mannose-1-phosphate guanylyltransferase (GMPPB). GDP-mannose is the activated mannose used to build N-linked glycans.
- GDP-mannose → lipid-linked oligosaccharide, assembled in the endoplasmic reticulum.
- lipid-linked oligosaccharide → transferred to asparagine on the protein, giving a glycoprotein.
- Later completion of the glycan, the steps whose defects give the type II transferrin pattern.
- PMM2-CDG (about 70% of CDG): the mannose-1-phosphate pool shrinks, GDP-mannose runs short, and too little lipid-linked oligosaccharide is made, so proteins are underglycosylated and work poorly. Features span brain (developmental delay, cerebellar hypoplasia), eyes (strabismus), heart (pericardial effusion), liver, and fat (inverted nipples, suprapubic fat pads). Procoagulant and anticoagulant glycoproteins both fall (factors IX and XI, antithrombin III, proteins C and S), so both bleeding and thrombosis occur. There is no specific treatment.
- Hereditary fructose intolerance: a secondary defect of glycosylation. Fructose-1-phosphate that builds up after a fructose exposure inhibits mannose phosphate isomerase, so protein glycosylation is impaired and the transferrin pattern can turn abnormal; it should correct once fructose is restricted and the liver disease subsides.
- Also on this pathway, without a page here yet: MPI-CDG, where dietary mannose bypasses the defective step and allows glycans to form, one of the few treatable CDGs; PGM1-CDG (treated with galactose) and SLC35C1-CDG (treated with fucose).
- Transferrin isoform analysis (carbohydrate-deficient transferrin) is the screen. Transferrin's glycans, which end in sialic acids, carry a negative charge, so missing or incomplete glycans change its charge, which isoelectric focusing or newer methods detect.
- A type I pattern (less tetrasialotransferrin, more asialo- and disialotransferrin) points to a defect in the earliest steps of N-glycan assembly, as in PMM2-CDG. A type II pattern (more trisialo- or monosialotransferrin) points to the later parts of the pathway.
- Low phosphomannomutase activity in leukocytes or fibroblasts confirms PMM2-CDG when genetic results are uncertain, and mass spectrometry of glycan structure can identify other subtypes.
- Read an abnormal pattern with the diet history and the clinical setting, because untreated fructose intolerance or galactosemia can produce a type I pattern, as can liver disease, severe infection, and chronic inflammatory disease.